Early breast and prostate cancer and clinical outcomes (fracture).
Osteoporosis is a skeletal disorder characterized by low bone mass that is associated with increased risk of fracture. Nearly 40% of the 12 million cancer survivors in the United States were diagnosed with breast and prostate cancer. Therapy for these two diseases is not uncommonly associated with bone loss related to hormone-ablative therapy. In women, this includes the use of endocrine therapies and chemotherapy-related premature menopause. In men, hormone-ablative therapies include gonadotropin-releasing hormone analogs and bilateral orchiectomy. Fracture risk assessment includes bone mineral density determination in appropriate populations and integration of findings with identified risk factors. Strategies to prevent and treat bone loss include nonpharmacologic and pharmacologic interventions. In the former case, regular weight-bearing and muscle-strengthening exercise is encouraged along with smoking cessation, modulation of alcohol consumption, and fall prevention. Supplementation with calcium and vitamin D decreases fracture risk in subgroups. Pharmacologic interventions include use of oral or intravenous bisphosphonates, selective estrogen receptor modulators, and calcitonin. Estrogen/menopause hormone therapies are not recommended for use in breast cancer survivors related to potential influence on recurrence. Strategies for management of bone loss in breast and prostate cancer are outlined by guidelines from the American Society of Clinical Oncology and the National Comprehensive Cancer Network.
Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA. rchlebowski@gmail.com
Rowan T
RT
Chlebowski
Tomoko
T
Tagawa
D000970:Antineoplastic Agents / Q000009:adverse effects*; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology* / Q000534:rehabilitation; D006727:Hormone Antagonists / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000534:rehabilitation; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D006727:Hormone Antagonists